BR112012011231A2 - novo tratamento da inflamação sistêmica de baixo grau - Google Patents

novo tratamento da inflamação sistêmica de baixo grau

Info

Publication number
BR112012011231A2
BR112012011231A2 BR112012011231A BR112012011231A BR112012011231A2 BR 112012011231 A2 BR112012011231 A2 BR 112012011231A2 BR 112012011231 A BR112012011231 A BR 112012011231A BR 112012011231 A BR112012011231 A BR 112012011231A BR 112012011231 A2 BR112012011231 A2 BR 112012011231A2
Authority
BR
Brazil
Prior art keywords
low
new treatment
systemic inflammation
grade systemic
inflammation
Prior art date
Application number
BR112012011231A
Other languages
English (en)
Inventor
Carl-Johan Dalsgaard
Johan Raud
Original Assignee
Cardoz Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardoz Ab filed Critical Cardoz Ab
Publication of BR112012011231A2 publication Critical patent/BR112012011231A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

novo tratamento da inflamação de baixo grau. de acordo com a invenção é fornecido pemirolast, ou um sal farmaceuticamente aceitável do mesmo, para uso no tratamento de inflamação sistêmica de baixo grau.
BR112012011231A 2009-11-13 2010-11-12 novo tratamento da inflamação sistêmica de baixo grau BR112012011231A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26094909P 2009-11-13 2009-11-13
PCT/GB2010/002096 WO2011058331A1 (en) 2009-11-13 2010-11-12 Pemirolast for the treatment of systemic low grade inflammation

Publications (1)

Publication Number Publication Date
BR112012011231A2 true BR112012011231A2 (pt) 2016-04-05

Family

ID=43479356

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011231A BR112012011231A2 (pt) 2009-11-13 2010-11-12 novo tratamento da inflamação sistêmica de baixo grau

Country Status (12)

Country Link
US (1) US20120329813A1 (pt)
EP (1) EP2498779A1 (pt)
JP (1) JP2013510837A (pt)
KR (1) KR20120115496A (pt)
CN (1) CN102724982A (pt)
AU (1) AU2010317712A1 (pt)
BR (1) BR112012011231A2 (pt)
CA (1) CA2780382A1 (pt)
EA (1) EA201200720A1 (pt)
IL (1) IL219710A0 (pt)
MX (1) MX2012005513A (pt)
WO (1) WO2011058331A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2303251B1 (en) * 2008-04-07 2012-05-16 Cardoz AB New combination for use in the treatment of inflammatory disorders
WO2016102941A1 (en) 2014-12-22 2016-06-30 Rspr Pharma Ab New combination of pemirolast and montelukast
KR102096204B1 (ko) * 2019-05-31 2020-04-02 최명석 국소지방 파괴 방법 및 국소지방 파괴용 저장성 용액

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2569398T3 (es) 2005-09-16 2016-05-10 Daiichi Sankyo Company, Limited Derivado de diamina ópticamente activo y proceso para producir el mismo
SI2120919T1 (sl) * 2006-12-18 2012-12-31 Cardoz Ab Nova kombinacija za uporabo pri zdravljenju vnetnih obolenj
WO2008075028A1 (en) * 2006-12-20 2008-06-26 Cardoz Ab New combination for use in the treatment of inflammatory disorders
CA2693628A1 (en) * 2007-07-11 2009-01-15 Cardoz Ab New combination for use in the treatment of imflammatory disorders
WO2009007679A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist
WO2009122182A1 (en) * 2008-04-04 2009-10-08 Cardoz Ab New combination for use in the treatment of inflammatory disorders
EP2303251B1 (en) * 2008-04-07 2012-05-16 Cardoz AB New combination for use in the treatment of inflammatory disorders
WO2010146341A2 (en) * 2009-06-16 2010-12-23 Cardoz Ab New crystalline form of pemirolast

Also Published As

Publication number Publication date
EP2498779A1 (en) 2012-09-19
CA2780382A1 (en) 2011-05-19
US20120329813A1 (en) 2012-12-27
MX2012005513A (es) 2012-06-19
WO2011058331A1 (en) 2011-05-19
EA201200720A1 (ru) 2013-02-28
CN102724982A (zh) 2012-10-10
KR20120115496A (ko) 2012-10-18
IL219710A0 (en) 2012-07-31
AU2010317712A1 (en) 2012-05-24
JP2013510837A (ja) 2013-03-28

Similar Documents

Publication Publication Date Title
BR112012011086A2 (pt) uso de betanecol para o tratamento de xerostomia
CL2012003656A1 (es) Uso de una composicion que comprende una enzima de reemplazo para la enzima lisosomal a una concentracion mayor a 5 mg/ml para tratar sintomas somaticos de la deficiencia de la enzima subyacente.
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
UY30333A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
EA201000210A1 (ru) Агонисты пиридон gpr119, сопряженного с g-белком рецептора
CL2008002294A1 (es) Compuestos derivados de benzotiazol acetamida y sus sales farmaceuticamente aceptables; composicion farmaceutica de dichos compuestos; su uso para tratar enfermedades mediadas por pi3 quinasa incluyendo melanoma, carcinoma y otras condiciones derivadas del cancer.
DOP2011000354A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
UY29899A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas
PA8657801A1 (es) Aminalcoholes triciclicos, procedimientos para su preparacion
UA109260C2 (uk) Хромонові похідні, спосіб їх одержання та їх терапевтичні застосування
CL2013003700A1 (es) Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.
UY32735A (es) Formulaciones de imiquimod de concentración de dosificación inferior y regímenes de dosificación cortos para tratar verrugas genitales y perianales.
CO6741197A2 (es) Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma
SV2010003701A (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
CL2012003282A1 (es) Composicion farmaceutica topica que comprende, en base al peso total de la composicion a) 0,01 a 0,2% en peso de furoato de mometasona, b) 5 a 18% en peso de hexilenglicol, c) 20 a 40% en peso de agua y d) 25 a 70% en peso de una fase oleosa; y su uso para tratar o prevenir psoriasis, dermatitis atopica, entre otros.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
BR112012011231A2 (pt) novo tratamento da inflamação sistêmica de baixo grau
ECSP10010661A (es) Dronedarona para la prevención de la cardioversión
SV2010003773A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]